Oppenheimer Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $135
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on Zimmer Biomet Holdings (NYSE:ZBH) but lowers the price target from $145 to $135.
October 15, 2024 | 12:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer has maintained its Outperform rating on Zimmer Biomet Holdings but has lowered the price target from $145 to $135, indicating a slightly less optimistic outlook.
The maintenance of an Outperform rating suggests continued confidence in Zimmer Biomet's performance, but the lowered price target indicates a tempered outlook. This could lead to neutral short-term price movement as the market digests the mixed signals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100